{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling, creating an inflammatory tumor microenvironment.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "The interferon response was measured using a normalized scoring system, and the strength of this effect varied across different mouse model systems rather than being uniform."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination expands the repertoire of tumor antigens presented on MHC-I molecules, improving tumor visibility to cytotoxic T cells.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        },
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        }
      ],
      "caveat": "These findings were derived from immunopeptidomics in preclinical models; human translation of antigen presentation changes was not directly measured."
    },
    {
      "claim_id": "C03",
      "claim": "Combined intratumoral mRNA vaccination and anti-PD-L1 therapy produces superior tumor control compared to either monotherapy in mouse models.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        }
      ],
      "caveat": "The efficacy data comes from preclinical mouse models; human combination therapy trials have not been conducted to confirm translatability."
    },
    {
      "claim_id": "C04",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival outcomes in metastatic cancer patients receiving immune checkpoint inhibitor treatment.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Human metastatic cohort: 130 patients total | Human vaccinated subgroup: 43 patients | Human unvaccinated subgroup: 87 patients",
          "line_ref": "L21-L23"
        }
      ],
      "caveat": "The human analysis is retrospective, non-randomized, and subject to confounding factors including variable vaccination timing and heterogeneous tumor types and treatment histories."
    }
  ]
}